Key result
Ticagrelor cuts major cardiovascular events by ~2 percentage points vs clopidogrel in ACS without extra major bleeding.
Why the study?
Do novel antiplatelet agents (e.g., ticagrelor, prasugrel) improve the prevention of cardiovascular complications in patients with atherothrombotic disease compared to standard dual antiplatelet therapy?
Do novel antiplatelet agents (e.g., ticagrelor, prasugrel) improve the prevention of cardiovascular complications in patients with atherothrombotic disease compared to standard dual antiplatelet therapy?
Novel P2Y12 receptor antagonists such as ticagrelor and prasugrel offer potential advantages over standard clopidogrel for secondary prevention of atherothrombotic events, though their full clinical utility requires further individualization.
Answers are grounded in this paper and cite their sources.
May support ticagrelor in ACS; leaves open optimal selection of novel P2Y12 agents.
Atherothrombosis, thrombus formation as a result of atherosclerotic plaque rupture, is a major modern health problem, often underlying coronary artery disease, stroke, and peripheral arterial disease. After the treatment of an acute thrombotic episode, long-term therapy is warranted as a secondary prophylaxis of such events and their complications. Because of the importance of platelets' involvement in the initiation and propagation of thrombosis, antiplatelet drugs have come to the forefront of atherothrombotic disease treatment. Dual antiplatelet therapy of aspirin plus clopidogrel--the current standard--has its benefits, but it also has its limitations with regard to its pharmacologic properties and adverse effects. For these reasons, within the last decade or so, the investigation of novel antiplatelet agents has prospered. Here, we review the main pathways through which platelets participate in acute thrombosis and the interruption of these pathways by using novel antiplatelet agents, including P2Y12 receptor antagonists (the recently approved prasugrel, the probable next-in-line ticagrelor, and others). The need for a more individualized patient therapy is evident; although most of the aforementioned pharmaceuticals have the potential to contribute to this, their clinical utility remains to be seen.
No takes yet. Share an insight, caveat, or question.
Marek Postuła (2010) conducted a review in Acute coronary syndromes (n=18,624). Ticagrelor vs. Clopidogrel (300 mg loading dose with an additional 300 mg at PCI, then 75 mg once daily) was evaluated on Composite of death from vascular causes, myocardial infarction, or stroke (p=<0.001). Ticagrelor reduced the rate of vascular death, MI, or stroke compared with clopidogrel without increasing overall major bleeding in ACS patients.
Synapse has enriched 10 related papers. Consider them for comparative context: